Clinical trial
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Breast Cancer Whose Disease Has Failed Prior Taxane-Based Treatment
NCT00802945 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Breast Cancer Whose Disease Has Failed Prior Taxane-Based Treatment
- Lead sponsor
- Nektar Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2008
- Completion date
- January 31, 2012
- Enrollment
- 70 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, tumor